🇺🇸 FDA
Patent

US 12180300

Targeting moiety-drug grafted immune cell compositions and methods of use

granted A61KA61K47/60A61K47/68033

Quick answer

US patent 12180300 (Targeting moiety-drug grafted immune cell compositions and methods of use) held by Arizona Board of Regents on Behalf of the University of Arizona expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arizona Board of Regents on Behalf of the University of Arizona
Grant date
Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K47/60, A61K47/68033, A61K47/6849, A61K47/6851